Figure 3. Dot-blot immunoassay for fluorescent detection of acid. Peptide-CPNs were deposited at the same concentration, and the concentration of each sample is double that of the previous sample. The graph represents the intensity of each spot: white circles correspond to PEK/F8BT, and black circles correspond to PEK-FA/F8BT. Figure 4. Cellular uptake of peptide-CPNs by HeLa cells in DMEM supplemented with 1% (v/v) FBS. (A) Representative confocal images of TAT/F8BT, anti-TAT/F8BT, and PEK/F8BT incubation with HeLa cells at 30 min, 2 h, 6 h, and 24 h (scale bars correspond to 50 actin staining is shown in red, nuclei staining is shown in blue, and peptide-CPNs fluorescing is shown in green). (B) Normalized flow cytometry data intracellular uptake in HeLa cells at 30 min, 2 h, 6 h, 9 h, and 24 h for all peptide-CPNs; red represents TAT/F8BT, blue represents green represents PEK/F8BT, and gray represents PEG-NH2/F8BT. Figure 5. (A) Schematic representation of major pinocytic pathways of nanoparticles in mammalian cells and of the inhibitors used for each pathway. (B) Flow cytometry data of intracellular uptake in HeLa cells after 2 h of TAT/F8BT incubation in DMEM supplemented with 1% (v/v) FBS. [Legend: (*) P < 0.05, (**) P < 0.001, and (***) P < 0.0001.] Figure 6. Determination of cytotoxicity of peptide-CPNs to HeLa cells with Alamar Blue and LDH assays after 24 h: (A) data for Alamar Blue, expressed relative to untreated controls, and
Figure 3. Dot-blot immunoassay for fluorescent detection of acid. Peptide-CPNs were deposited at the same concentration, and the concentration of each sample is double that of the previous sample. The graph represents the intensity of each spot: white circles correspond to PEK/F8BT, and black circles correspond to PEK-FA/F8BT. Figure 4. Cellular uptake of peptide-CPNs by HeLa cells in DMEM supplemented with 1% (v/v) FBS. (A) Representative confocal images of TAT/F8BT, anti-TAT/F8BT, and PEK/F8BT incubation with HeLa cells at 30 min, 2 h, 6 h, and 24 h (scale bars correspond to 50 actin staining is shown in red, nuclei staining is shown in blue, and peptide-CPNs fluorescing is shown in green). (B) Normalized flow cytometry data intracellular uptake in HeLa cells at 30 min, 2 h, 6 h, 9 h, and 24 h for all peptide-CPNs; red represents TAT/F8BT, blue represents green represents PEK/F8BT, and gray represents PEG-NH2/F8BT. Figure 5. (A) Schematic representation of major pinocytic pathways of nanoparticles in mammalian cells and of the inhibitors used for each pathway. (B) Flow cytometry data of intracellular uptake in HeLa cells after 2 h of TAT/F8BT incubation in DMEM supplemented with 1% (v/v) FBS. [Legend: (*) P < 0.05, (**) P < 0.001, and (***) P < 0.0001.] Figure 6. Determination of cytotoxicity of peptide-CPNs to HeLa cells with Alamar Blue and LDH assays after 24 h: (A) data for Alamar Blue, expressed relative to untreated controls, and
AlmeidaC-ChemMater-2015-accepted-version.docx